# LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial

Study · id `cardio:ct-nct07645300` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07645300](<https://clinicaltrials.gov/study/NCT07645300>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07645300

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 160 participants.

## Technical summary

Registry record NCT07645300. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-01 (anticipated); primary completion 2032-03-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT07645300, source copy `cardio:ctgov-nct07645300-2026-06-12`, retrieved 2026-10-26)
- Planned start: 2026-10-01 (anticipated) (ClinicalTrials.gov record NCT07645300, source copy `cardio:ctgov-nct07645300-2026-06-12`, retrieved 2026-10-26)
- Primary completion: 2032-03-31 (anticipated) (ClinicalTrials.gov record NCT07645300, source copy `cardio:ctgov-nct07645300-2026-06-12`, retrieved 2026-10-26)
- Completion: 2032-06-30 (anticipated) (ClinicalTrials.gov record NCT07645300, source copy `cardio:ctgov-nct07645300-2026-06-12`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07645300, source copy `cardio:ctgov-nct07645300-2026-06-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07645300-2026-06-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial
- Acronym: LODESTAR
- Condition: Hypertension Treated With Antihypertensive Drugs
- Condition: Chronic Kidney Disease, 3B and 4
- Intervention (Drug): phase 2A Chlorthalidone
- Intervention (Drug): phase 2A Spironolactone
- Intervention (Drug): phase 2A Chlorthalidone + Spironolactone
- Intervention (Drug): phase 2B Chlorthalidone LD + Spironolactone LD
- Lead sponsor: VA Office of Research and Development
- Lead sponsor class: FED
- Collaborator: Michael E. DeBakey VA Medical Center
- Collaborator class: FED
- Collaborator: VA Salt Lake City Health Care System
- Collaborator class: FED

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: VA Office of Research and Development (`cardio:org-va-office-of-research-and-development`)

## Provenance

Content hash: a722f9c02b502df51e143bbe7f4a51fb2c8c3da4838f67c3215608d1ef2e74db
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
